Kite Pharma (KITE) Tops Q3 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
No Surpises in Kite Pharma (KITE) Q3, Mizuho Says; Positive Ahead of ASH
November 13, 2015 7:36 AM ESTMizuho Securities analyst Eric Criscuolo reiterated a Buy rating and $90 price target on Kite Pharma (NASDAQ: KITE) following Q3 results and with ASH approaching.
Criscuolo commented, "There were no major updates in KITE's 3Q earnings. We reiterate our Buy rating with the ASH... More
